Researchers at the Stanford University in the US found that the magnitude and quality of a key immune cell's response to vaccination with two doses of the Pfizer-BioNTech Covid-19 vaccine were considerably lower in people with prior SARS-CoV-2 infection compared to people without prior infection.In a